OBIO and MDT Related Headlines
Go Back- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed targets BACKBEAT trial completion by Q3 2026
- Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
- Orchestra BioMed receives $20 million from Medtronic under financing pact
- Orchestra BioMed receives $15 million from Ligand under financing agreement
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
- Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
- Orchestra BioMed presents data showing sustained blood pressure drops
- Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
OBIO and MDT Related Press Releases
Go Back- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
- Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
- Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
